ICD-10 Code C50.411: Right Breast Cancer Coding Guide 2026

Key Takeaways

C50.411 is a billable 2026 ICD-10-CM code for malignant neoplasm of the upper-outer quadrant of the right female breast.

The code is both gender-specific (female) and laterality-specific (right side) – using an unspecified or wrong-side code triggers claim denials.

C50.411 maps to ICD-9-CM code 174.4 and carries HCC risk-adjustment implications under CMS risk models.

Pabau’s claims management software supports oncology billing workflows with accurate diagnosis code capture and clean claim submission.

Breast cancer denials rarely come from wrong clinical information – they come from missing specificity. A coder who submits C50.9 (unspecified breast, unspecified site) instead of ICD-10 Code C50.411 is leaving the claim exposed: payers routinely reject or downcode claims where laterality and anatomical site are available but absent from the submission. For oncology and women’s health practices billing primary breast malignancies in the right upper-outer quadrant, C50.411 is the only code that satisfies that specificity requirement.

This reference covers the full definition of ICD-10 Code C50.411, its billability status for 2026, the code hierarchy it sits within, laterality and site-specificity rules, adjacent C50 codes, the ICD-9-CM crosswalk, documentation requirements, and commonly associated CPT codes. It is written for healthcare coders, oncology billing teams, and medical practices managing breast cancer claims.

ICD-10 Code C50.411: Definition and Clinical Description

ICD-10 Code C50.411 describes a malignant neoplasm (primary cancer) located in the upper-outer quadrant of the right female breast. For the right breast, the upper-outer quadrant (UOQ) extends from approximately the 9 o’clock to 12 o’clock position when visualized as a clock face centered on the nipple – corresponding to the lateral (toward the axilla) and superior (upper) portion of the breast. (For comparison, the upper-outer quadrant of the LEFT breast spans 12 o’clock to 3 o’clock.) Epidemiologically, this quadrant accounts for the highest proportion of breast cancer diagnoses, making C50.411 one of the most frequently used codes in the entire C50 category.

The code sits within the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), maintained jointly by the Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS). C50.411 is a valid, billable, specific code for fiscal year 2026, unchanged from prior years and applicable to all payer types requiring ICD-10-CM diagnosis coding.

For oncology and surgical practices managing breast cancer cases, using C50.411 correctly is non-negotiable. It triggers specific reimbursement pathways, HCC risk-adjustment categories, and prior authorization workflows that an unspecified C50.9 code cannot activate.

Billable Status and Applicable Diagnoses

C50.411 is classified as a billable/specific code. This means it carries sufficient anatomical detail for claim submission – coders do not need to use a more general parent code. According to ICD List, the code has been valid and billable continuously since ICD-10-CM was implemented in the United States in October 2015.

• Gender restriction: Female diagnoses only. This code cannot be assigned to male patients.
• Laterality: Right breast only. Left breast uses C50.412; unspecified side uses C50.419.
• Primary malignancy only: C50.411 describes a primary tumor. Metastatic disease from the breast to other sites uses different code ranges (C77-C79).
• Histology-agnostic: The code applies regardless of histological subtype (ductal, lobular, inflammatory, etc.) – histology detail is captured separately where needed.

Code Hierarchy and ICD-10 Code C50.411 Classification

Understanding where ICD-10 Code C50.411 sits in the classification tree helps coders navigate the C50 category and select correctly when multiple adjacent codes could apply. The full hierarchy from broadest to most specific is:

C50.41 is the non-billable parent code for all upper-outer quadrant, female breast malignancies. Coders must always select the most specific child code (C50.411, C50.412, or C50.419) rather than stopping at C50.41. Submitting C50.41 on a claim will result in an invalid code error from most clearinghouses. The CDC/NCHS ICD-10-CM web tool confirms this hierarchy and can be used to validate code specificity before submission.

The NCI Metathesaurus maps C50.411 to concept C2842105, providing a crosswalk between ICD-10-CM and oncology-specific terminology used in cancer registries and research databases. This mapping supports interoperability between clinical documentation systems, oncology EMR platforms, and payer claims systems.

Adjacent C50 Codes and Laterality Distinctions for ICD-10 Code C50.411

The C50 category is organized by anatomical site within the breast and by laterality. Getting the laterality wrong – particularly submitting a left-side code for a right-side tumor – is one of the most common audit triggers for breast cancer claims. The table below shows the codes most likely to be confused with C50.411.

The distinction between C50.411 (upper-outer) and C50.511 (lower-outer) hinges entirely on the documented quadrant in the pathology report or operative note. Coders should never select a quadrant code without a supporting clinical document specifying the anatomical location. When multiple quadrants are involved, ICD-10-CM coding guidelines (which can be referenced through AAPC Codify) provide direction on which code takes precedence. For patients with bilateral breast cancer, both C50.411 and C50.412 may be assigned simultaneously – they are not mutually exclusive.

Practices focused on women’s health and gynecologic oncology will encounter this code family frequently. Establishing a clear internal coding protocol for laterality verification reduces the rate of rework on rejected claims.

ICD-9-CM Crosswalk: C50.411 and Code 174.4

For practices reconciling historical records, insurance correspondence referencing legacy codes, or researchers working with pre-2015 claims data, ICD-10 Code C50.411 maps to ICD-9-CM code 174.4 (Malignant neoplasm of upper-outer quadrant of female breast). This is a one-to-one approximate conversion: the ICD-9 code did not carry laterality specificity, which is why a single ICD-9 code (174.4) expands to three ICD-10-CM codes (C50.411, C50.412, C50.419) in the forward mapping.

When working with crosswalks, coders must remember that the conversion is directional and approximate – not exact. A 174.4 claim from 2014 cannot be assumed to represent a right-side tumor just because C50.411 is the forward-mapped code. The conversion must always be validated against original clinical documentation. This matters most for cancer registry updates, retroactive audits, and prior authorization appeals where historical coding is compared to current submissions.

Maintaining accurate cross-version coding references within your practice’s clinical documentation system reduces the risk of mismatched diagnosis histories when payers request supporting records. For similar crosswalk principles applied to other diagnostic categories, the same ICD-9-to-ICD-10 logic applies across the full C-chapter malignancy codes.

Documentation Requirements for ICD-10 Code C50.411

Three documentation elements are required to support C50.411 on a claim. Missing any one of them creates a medical necessity vulnerability if the claim is audited.

1. Confirmed malignancy: A pathology report confirming carcinoma (or equivalent histological classification) must be present in the patient record. Clinical suspicion alone does not support C50.411 – coders should use the appropriate “uncertain behavior” neoplasm code (D48.6x series) while awaiting pathology confirmation.
2. Laterality documentation: The treating physician, surgeon, or radiologist must explicitly state “right breast” or equivalent language in a clinical note, imaging report, or operative record. Laterality cannot be inferred from treatment plans or side-of-body indicators alone.
3. Anatomical site specificity: The upper-outer quadrant must be named or described in clinical documentation. Acceptable sources include: mammography reports, ultrasound findings, MRI reports, biopsy reports, and surgical operative notes. Phrases like “outer upper quadrant,” “lateral superior breast,” or “10 o’clock position” are clinically acceptable as long as they clearly indicate the UOQ.

Under HIPAA-compliant documentation practices, all supporting records must be retained and linkable to the claim. The American Health Information Management Association (AHIMA) recommends that coding decisions for malignancy claims be traceable to a specific document in the medical record – not derived from the claim form or billing system alone.

Practices using digital intake and clinical forms can build laterality and anatomical site fields directly into their oncology documentation templates, ensuring providers capture this information at the point of care rather than retrospectively.

HCC Risk Adjustment Implications

Under the CMS-HCC V28 risk adjustment model – which is fully effective for 100% of Medicare Advantage risk score calculations in payment year 2026 (following the V24/V28 phase-in of 33% V28 in 2024 and 67% V28 in 2025) – C50.411 maps to HCC 23 (Prostate, Breast, and Other Cancers and Tumors). Under the prior V24 model, this code mapped to HCC 12 (Breast, Prostate, Colorectal and Other Cancers and Tumors), which V28 split into multiple distinct categories. The V28 mapping carries a meaningful risk score coefficient – meaning that accurate coding of C50.411 for a Medicare Advantage or value-based care patient directly affects the capitated payment the practice or plan receives for that patient’s care. Practices under risk-bearing contracts who consistently under-code breast malignancies (e.g., using C50.919 instead of C50.411) may find their risk scores understated, resulting in payment shortfalls that do not reflect the actual clinical complexity of the patient population.

Annual HCC validation audits should include a breast cancer cohort review: confirm that all patients with documented C50.411 have the code submitted on at least one qualifying claim per calendar year. Claims management software that tracks diagnosis code usage across a patient’s episode of care can flag cases where the primary malignancy code was dropped after the initial visit.

Streamline Oncology Billing with Pabau

Pabau's claims management tools help oncology and women's health practices capture the right diagnosis codes at every visit, reduce denials, and track claims through to payment.

Book a demo

Associated CPT Codes Commonly Billed with C50.411

ICD-10 Code C50.411 appears as a primary diagnosis code paired with a wide range of CPT procedure codes depending on the phase of care. The table below summarizes the most common pairings by service category. These represent general clinical practice – coders should always verify medical necessity linkage for the specific payer before submitting.

Coders working with chemotherapy infusion claims should note that CPT codes 96413 and 96415 carry their own medical necessity requirements. Payers often require the specific chemotherapy agent reported via a corresponding HCPCS J-code (such as J9355 for trastuzumab or J9070 for cyclophosphamide) alongside C50.411. For a broader overview of similar procedure code reference structures, see our procedure code reference guide.

Radiation oncology pairings with C50.411 frequently require prior authorization. Most commercial payers require the treating oncologist to document tumor location (consistent with the coded quadrant), treatment intent (curative vs. palliative), and the anticipated number of fractions. Accurate use of C50.411 – rather than an unspecified breast code – is often required to satisfy the clinical necessity criteria in these authorization requests. Practices using structured diagnostic coding workflows reduce the back-and-forth on authorization delays.

Expert Resources for ICD-10 Code C50.411 Coding Workflows

Expert Picks

Need a compliance-ready documentation framework? HIPAA Compliance for Medical Offices covers how to structure clinical records to support diagnostic code defensibility in audits.

Managing multi-specialty oncology billing? Pabau Claims Management Software helps practices track diagnosis codes across visits and flag missing laterality before claims are submitted.

Expanding into women’s health oncology workflows? Pabau OB/GYN EMR Software provides specialty-specific documentation templates designed for gynecologic and breast oncology practices.

Conclusion

Laterality errors in breast cancer coding cost practices time and money – rejected claims, authorization delays, and HCC underpayments all trace back to insufficient specificity. ICD-10 Code C50.411 solves that problem for right upper-outer quadrant malignancies, but only when the underlying documentation supports it. Pathology confirmation, explicit right-side notation, and documented anatomical site are the three pillars every claim needs.

Pabau’s claims management software helps oncology and women’s health practices build those documentation checks into every workflow – from intake to claim submission. If your team is managing a high volume of breast cancer billing, book a demo to see how Pabau reduces denial rates on complex oncology claims.

Frequently Asked Questions